BRAF and melanoma: RNA-based assays are instead preferable for detecting BRAF fusions which occur at low frequencies in melanoma (3%), glioma (2%) thyroid cancer (1%), pancreatic carcinoma (0.3%), NSCLC (0.2%), and colorectal cancer (0.2%) [117].